Research led by Jack Tseng, PhD, assistant professor of pathology and anatomical sciences, found that a wolf-sized otter that lived about 6 million years ago may have been a dominant predator in its time.
David L. Kaye, MD, professor of psychiatry, is receiving national recognition for a program he developed to address New York state’s critical shortage of child and adolescent psychiatrists in a cost-effective way.
New clues to non-alcoholic fatty liver disease (NAFLD), which affects nearly all obese adults and a rising percentage of obese children, have been reported in a paper by senior author Susan S. Baker MD, PhD.
Anne B. Curtis, MD, SUNY Distinguished Professor and Charles and Mary Bauer Professor and chair of the Department of Medicine, is a member of the committee that has issued a new practice guideline for treating sudden cardiac death (SCD).
Four studies focused on improving our understanding of the human genome and microbiome have been awarded funding through the third round of research pilots supported by the Community of Excellence in Genome, Environment and Microbiome (GEM).
Six faculty, three retired faculty and two staff members from the Jacobs School of Medicine and Biomedical Sciences were among those honored for notable achievement and service at the 14th annual University at Buffalo Celebration of Faculty and Staff Academic Excellence.
A new book co-edited by Mulchand S. Patel, PhD, SUNY Distinguished Professor of biochemistry, discusses how the path to obesity may start before birth or during infancy and how an individual’s metabolism can be permanently reprogrammed by overfeeding early in life.
A newly patented technology developed as a collaboration in the departments of Biomedical Engineering, Orthopaedics, and Microbiology and Immunology is at the heart of an Office of Naval Research (ONR) grant focused on preventing and treating orthopaedic implant-related infections.
A global study led by Paresh Dandona, MD, PhD, found a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels.